Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial

Lancet

Volumn 356, Issue 9247, 2000, Pages 2052-2058

  Køber, Lars ^a   Bloch Thomsen, Poul Erik ^a   Møller, Mogens ^b   Torp Pedersen, Christian ^a   Carlsen, Jan ^c   Sandøe, Erik ^d   Egstrup, Kenneth ^e   Agner, Erik ^f   Videbæk, Jørgen ^g   Marchant, Bradley ^h   Camm, A John ⁱ  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Medicon Contract Research Organisation   (Denmark)

^d Rigshospitalet   (Denmark)

^e Haderslev Hospital   (Denmark)

^f Elsinore Hospital   (Denmark)

^g BISPEBJERG HOSPITAL   (Denmark)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

ⁱ ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOFETILIDE; PLACEBO;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY CARE UNIT; DENMARK; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; TREATMENT OUTCOME;

EID: 0034676762     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03402-4     Document Type: Article

References (37)

1. Prognosis after initial myocardial infarction: The Framingham study
2. An echocardiographic method for Selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies
3. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction
4. Variables predictive of survival in patients with coronary disease: Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations
5. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction: The Western Washington Intracoronary Streptokinase Trial
6. Risk stratification and survival after myocardial infarction
7. Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction
8. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial
9. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction
10. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period
11. Clinical studies on beta blockers and heart failure preceding the MERIT-HF Trial
12. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia
13. Myocardial catecholamines and the pathophysiology of heart failure
14. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial
15. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
16. International Mexiletine and Placebo Antiarrhythmic Coronary Trial: I, report on arrhythmia and other findings
17. Effect of d-sotalol on mortality in patients with left-ventricular dysfunction after recent and remote myocardial infarction
18. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)
19. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
20. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
21. Rapid suppression of complex ventricular arrhythmias with high-dose oral amiodarone
22. Amiodarone: Historical development and pharmacologic profile
23. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials
24. Adverse effects of low close amiodarone: A meta-analysis
25. UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells
26. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide
27. Electrophysiologic and hemodynamic effects of dofetilide in patients with depressed left ventricular function: A randomized, double-blind, placebo-controlled study
28. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris
29. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study
30. A randomized, double-blind, placebo-controlled comparison of intravenous dofetilide and procainamide in the acute conversion of atrial fibrillation/flutter
31. Conversion of AF and maintenance of sinus rhythm by dofetilide
32. Efficacy and safety of oral dofetilide in maintaining normal sinus in patients with atrial fibrillation/flutter: A multicenter study
33. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
34. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale design, and patient characteristics of the DIAMOND studies
35. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography
36. Prediction of creatinine clearance from serum creatinine
37. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (The Cardiac Arrhythmia Pilot Study)